Myriad Genetics (MYGN) Revenue (2009 - 2026)

Myriad Genetics (MYGN) has 18 years of Revenue data on file, last reported at $200.4 million in Q1 2026.

• Revenue for Q1 2026 came in at $200.4 million, up 2.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $829.0 million (changed 0.28% YoY), and the FY2025 annual result was $824.5 million, down 1.56% from the prior year.
• Revenue declined to $200.4 million in Q1 2026 per MYGN's latest filing, from $209.8 million in the prior quarter.
• Over five years, Revenue peaked at $213.3 million in Q3 2024 and troughed at $156.4 million in Q3 2022.
• A 5-year average of $193.8 million and a median of $196.6 million in 2023 frame the typical range for Revenue.
• The sharpest annual moves came in 2022 and 2023: Revenue declined 6.52% in 2022, then rose 22.7% in 2023.
• A 5-year view of Revenue shows it stood at $177.8 million in 2022, then increased by 10.57% to $196.6 million in 2023, then grew by 7.12% to $210.6 million in 2024, then fell by 0.38% to $209.8 million in 2025, then retreated by 4.48% to $200.4 million in 2026.
• Business Quant data shows MYGN's Revenue at $200.4 million in Q1 2026, $209.8 million in Q4 2025, and $205.7 million in Q3 2025.